<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Database (Oxford)</journal-id>
    <journal-id journal-id-type="iso-abbrev">Database (Oxford)</journal-id>
    <journal-id journal-id-type="publisher-id">databa</journal-id>
    <journal-title-group>
      <journal-title>Database: The Journal of Biological Databases and Curation</journal-title>
    </journal-title-group>
    <issn pub-type="epub">1758-0463</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
      <publisher-loc>UK</publisher-loc>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">9394491</article-id>
    <article-id pub-id-type="doi">10.1093/database/baac072</article-id>
    <article-id pub-id-type="publisher-id">baac072</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Original Article</subject>
      </subj-group>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI00960</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>Phosprof: pathway analysis database of drug response based on phosphorylation activity measurements</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1228-2629</contrib-id>
        <name>
          <surname>Kagiwada</surname>
          <given-names>Harumi</given-names>
        </name>
        <!--h-kagiwada@aist.go.jp-->
        <xref rid="COR0001" ref-type="corresp"/>
        <aff><institution content-type="department">Cellular and Molecular Biotechnology Research Institute, National Institute of Advanced Industrial Science and Technology</institution>, 2-4-7, Aomi Koto-ku, Tokyo, <country country="JP">Japan</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Motono</surname>
          <given-names>Chie</given-names>
        </name>
        <aff><institution content-type="department">Cellular and Molecular Biotechnology Research Institute, National Institute of Advanced Industrial Science and Technology</institution>, 2-4-7, Aomi Koto-ku, Tokyo, <country country="JP">Japan</country></aff>
        <aff><institution>AIST-Waseda University Computational Bio Big-Data Open Innovation Laboratory (CBBD-OIL)</institution>, 3-4-1, Okubo Shinjuku-ku, Tokyo 169-8555, <country country="JP">Japan</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Horimoto</surname>
          <given-names>Katsuhisa</given-names>
        </name>
        <aff><institution content-type="department">Artificial Intelligence Research Center, National Institute of Advanced Industrial Science and Technology</institution>, 2-4-7, Aomi Koto-ku, Tokyo, <country country="JP">Japan</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2482-8481</contrib-id>
        <name>
          <surname>Fukui</surname>
          <given-names>Kazuhiko</given-names>
        </name>
        <!--k-fukui@aist.go.jp-->
        <xref rid="COR0001" ref-type="corresp"/>
        <aff><institution content-type="department">Cellular and Molecular Biotechnology Research Institute, National Institute of Advanced Industrial Science and Technology</institution>, 2-4-7, Aomi Koto-ku, Tokyo, <country country="JP">Japan</country></aff>
        <aff><institution>AIST-Waseda University Computational Bio Big-Data Open Innovation Laboratory (CBBD-OIL)</institution>, 3-4-1, Okubo Shinjuku-ku, Tokyo 169-8555, <country country="JP">Japan</country></aff>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="COR0001">*Corresponding author: Tel: +81 3 5501 1017; Fax: +81 3 5530 2061; Email: <email xlink:href="h-kagiwada@aist.go.jp">h-kagiwada@aist.go.jp</email>Correspondence may also be addressed to Kazuhiko Fukui. Tel: +81 3 3599 8667; Fax: +81 3 5530 2061; Email: <email xlink:href="k-fukui@aist.go.jp">k-fukui@aist.go.jp</email></corresp>
    </author-notes>
    <pub-date pub-type="collection">
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2022-08-22">
      <day>22</day>
      <month>8</month>
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>22</day>
      <month>8</month>
      <year>2022</year>
    </pub-date>
    <volume>2022</volume>
    <elocation-id>baac072</elocation-id>
    <history>
      <date date-type="received">
        <day>15</day>
        <month>3</month>
        <year>2022</year>
      </date>
      <date date-type="rev-recd">
        <day>19</day>
        <month>7</month>
        <year>2022</year>
      </date>
      <date date-type="accepted">
        <day>17</day>
        <month>8</month>
        <year>2022</year>
      </date>
      <date date-type="editorial-decision">
        <day>11</day>
        <month>8</month>
        <year>2022</year>
      </date>
      <date date-type="corrected-typeset">
        <day>22</day>
        <month>8</month>
        <year>2022</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2022. Published by Oxford University Press.</copyright-statement>
      <copyright-year>2022</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p>
      </license>
    </permissions>
    <self-uri xlink:href="baac072.pdf"/>
    <abstract>
      <title>Abstract</title>
      <p>Protein phosphorylation plays a fundamental role in many cellular processes. Proteins are phosphorylated by kinases, which have been studied as drug targets for the treatment of various diseases, particularly cancer. Because kinases have multiple roles in interconnected molecular pathways, their specific regulation is required to enhance beneficial and reduce adversarial effects of drugs. Using our previously developed platform, we measured phosphorylation profiles of MCF7 and K562 cells treated with 94 clinical drugs. These phosphorylation profiles can provide insights into pathway activities and biological functions. Here, we introduce Phosprof, a novel database of drug response based on phosphorylation activity. Phosprof is able to present up- or downregulated phosphorylated signature proteins on pathway maps, significant pathways on the hierarchal tree in signal transduction and commonly perturbed pathways affected by the selected drugs. It also serves as a useful web interface for new or known drug profile search based on their molecular similarity with the 94 drugs. Phosprof can be helpful for further investigation of drug responses in terms of phosphorylation by utilizing the various approved drugs whose target phenotypes are known.</p>
      <sec id="s2">
        <title>Database URL</title>
        <p>
          <ext-link xlink:href="https://phosprof.medals.jp/" ext-link-type="uri">https://phosprof.medals.jp/</ext-link>
        </p>
      </sec>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Japan Agency for Medical Research and Development</institution>
            <institution-id institution-id-type="DOI">10.13039/100009619</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>21ae0101074s0203</award-id>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="7"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec id="s3">
    <title>Introduction</title>
    <p>Protein kinases play key roles in multiple biological events (<xref rid="R1" ref-type="bibr">1</xref>). Kinases transduce signals through phosphorylation chain reactions via the pathway proteins, leading to appropriate cellular responses to cues from the external environment or from cell–cell communications (<xref rid="R2" ref-type="bibr">2</xref>). Kinases have been studied as drug targets in various diseases, since their dysfunctions are associated with pathologies, such as overactivation of kinases in cancer (<xref rid="R3" ref-type="bibr">3</xref>). Therefore, it is important to evaluate the role of kinase activities in the context of biological functions and diseases.</p>
    <p>Large datasets of protein phosphorylation have been generated using mass spectrometry (<xref rid="R4" ref-type="bibr">4–6</xref>). Mass spectrometry measurements can provide information on modified amino acids. However, in some cases, quantitative studies face challenges in measuring labeled peptides or peptides of proteins present at varying levels in cells (<xref rid="R7" ref-type="bibr">7</xref>). In contrast, protein arrays accommodate controlled quantities of synthesized proteins and allow comprehensive measurements of protein phosphorylation levels by a simple reaction and detection method (<xref rid="R8" ref-type="bibr">8</xref>). The resultant datasets of phosphorylation levels of the arrayed proteins (‘phosphorylation profiles’) are suitable for quantitative studies and analyses (<xref rid="R9" ref-type="bibr">9</xref>). Phosphorylation profiles of various kinases have been generated to elucidate kinase–substrate relationships (<xref rid="R10" ref-type="bibr">10</xref>).</p>
    <p>We previously developed a novel platform for protein array phosphorylation measurement and pathway analysis (<xref rid="R11" ref-type="bibr">11</xref>). We designed a protein array containing 1373 native proteins of 376 ‘pathway maps’, which are assigned as ‘signal transduction’ pathways in the public database Reactome (<xref rid="R12" ref-type="bibr">12</xref>). We measured phosphorylation activities using this native protein array. We examined the performance of our array by detecting kinase–substrate relationships (<xref rid="R11" ref-type="bibr">11</xref>). Using the measured data (namely ‘phosphorylation profiles’), significant pathways were identified in growth-factor-stimulated cells (<xref rid="R11" ref-type="bibr">11</xref>) or drug-treated clinical cancer cells (<xref rid="R13" ref-type="bibr">13</xref>, <xref rid="R14" ref-type="bibr">14</xref>).</p>
    <p>In this study, we generated a novel dataset using drug-treated cells to develop a new database, Phosprof. In this database, we illustrate the changes in the phosphorylation activities in cells treated with 94 drugs and the results of pathway analysis. We selected 94 bioactive compounds with a wide range of applications in preclinical research of human diseases. We analyzed the obtained data and compared the results to examine the relationships between pathways and the known functions of these drugs.</p>
  </sec>
  <sec id="s4">
    <title>Data collection and analysis</title>
    <sec id="s4-s1">
      <title>Experiments</title>
      <p>We generated the phosphorylation profile by applying cell lysate to a protein array. As illustrated in <xref rid="F1" ref-type="fig">Figure 1</xref>, cultured cells (MCF7; human breast adenocarcinoma cells, ECACC, #86012803 and K562; human chronic myelogenous leukemia cells, ECACC, #89121407) were treated with 94 drugs from the L2400 Pfizer-licensed library (Selleck Inc.). These compounds were developed and validated by Pfizer. They have been marketed or clinically proven, and detailed preclinical research data and safety information are available from the manufacturer. Cells were cultured with each drug at a concentration of 10 μM or vehicle control (Dimethyl sulfoxide (DMSO) or water) for 2 h and lysed, and the obtained lysate was applied to the protein array with additional ATP.</p>
      <fig position="float" id="F1" fig-type="figure">
        <label>Figure 1.</label>
        <caption>
          <p>Scheme of the data collection and analysis for Phosprof. (Left) A drug from the Selleck L2400 Library was added to the cell culture media 2 h prior to the harvest of the cell lysate, which was then applied to a protein array with ATP. The tyrosine residues of the proteins on the array are phosphorylated by the cell lysate and detected using 4G10 antibody. (Right) The resultant ‘phosphorylation profiles’ were then analyzed to identify the significant pathways. The collected data can be browsed using various pathway analysis tools.</p>
        </caption>
        <graphic xlink:href="baac072f1" position="float"/>
      </fig>
      <p>Phosphorylation activity was measured as described previously (<xref rid="R11" ref-type="bibr">11</xref>). Briefly, 1373 signal transduction proteins with glutathione S-transferase-tag were synthesized and loaded onto a glutathione-coated glass slide. Every protein was spotted (approximately 500 nl per spot) six times (<italic toggle="yes">n</italic> = 6) per slide while ensuring that they were neither denatured nor dried. During spotting, humidity was maintained at 40–60%, and the wetness of each drop was confirmed by microscopic observation of the liquid droplets. Cell lysates including 100 μg of total protein were applied to an array with additional ATP at 30°C for 3 h. After the termination of the kinase reaction, the array was washed with Tris Buffered Saline with 0.05% Tween20 (TBST) and stained with the 4G10 phosphorylated protein-specific antibody (Merck, #05-1050) and a secondary fluorescein-conjugated antibody (Thermo, #A21235) to detect the phosphorylated tyrosine residues.</p>
    </sec>
    <sec id="s4-s2">
      <title>Analysis</title>
      <p>The difference expression of phosphorylation between the vehicle control and experimental samples was analyzed for raw and standardized data using the rank product test and Pearson’s correlation test using the R program (R Core Team, version 4.0.5). Signature proteins with increased and decreased phosphorylation levels were projected onto a full and simplified pathway map. A total of 376 pathways were integrated into four major functional groups—receptor tyrosine kinase (RTK) pathways (Group 1), Wnt–Hh pathways (Group 2), G-protein-coupled receptor (GPCR) pathways (Group 3) and cell death pathways (Group 4)—to precisely visualize pathways among the entire network of pathways that were perturbed by treatment with each drug. For legibility, we provide two types of pathway maps: full pathways containing all the 1373 proteins as pathway nodes and simple pathways with integrated nodes of complex proteins or protein groups.</p>
      <p>Signature proteins based on the rank product were used to calculate the hypergeometric distribution of the 376 pathways as enrichment analysis to determine the significant pathways. We performed sequence analysis of the 1373 proteins on the array using IUPred for disorder prediction (<xref rid="R15" ref-type="bibr">15</xref>).</p>
    </sec>
    <sec id="s4-s3">
      <title>Web interface</title>
      <p>All the metadata in Phosprof are managed by the SQLite database. The website is implemented in Django, which is a high-level Python framework. The upregulated and downregulated phosphorylated proteins were projected onto the pathway using our own developed program in ‘signature protein’ on the web. The pathway hierarchy of Reactome (<xref rid="R12" ref-type="bibr">12</xref>) in ‘pathway’ is visualized using graphviz. The Venn diagrams of ‘compare pathway’ for multiple-drug analysis are drawn using D3.js (Data-Driven Documents; <ext-link xlink:href="https://d3js.org/" ext-link-type="uri">https://d3js.org/</ext-link>). Open Babel is used to obtain Tanimoto coefficients between a simplified molecular input line entry system (SMILES) string and 94 representative clinical drugs in ‘Drug Search’. Significant molecules or pathways can be browsed, compared, and linked to further detailed information in the Protein Data Bank archive (PDB) (<xref rid="R16" ref-type="bibr">16</xref>) or Reactome (<xref rid="R12" ref-type="bibr">12</xref>). The detailed instructions for Phosprof are provided in the UserGuide (<xref rid="s7" ref-type="sec">Supplementary Material</xref>).</p>
    </sec>
  </sec>
  <sec id="s5">
    <title>Database features and applications</title>
    <sec id="s5-s1">
      <title>Signature protein</title>
      <p>Cultured cells (MCF7 and K562) were treated with each of the 94 drugs and lysed, and the lysates were subjected to phosphorylation activity measurements using protein arrays. Phosphorylation of the array proteins was detected using staining with the 4G10 antibody, and the measured data were stored in the Phosprof database. We monitored tyrosine phosphorylation using the 4G10 antibody, which exhibits high sensitivity. Using this strategy, we successfully assessed the activity of signal transduction pathways associated with the functional cellular states (<xref rid="R11" ref-type="bibr">11</xref>). The differences between the vehicle control (treated with DMSO or water) and experimental samples (treated with a drug) were analyzed for stored raw or standardized data using the rank product test and Pearson’s correlation. These results are summarized in the ‘Signature Protein’ section. The signature proteins whose phosphorylation levels were changed significantly by the drug treatment can be browsed in Phosprof by selecting the drug of interest on the top page (<xref rid="F2" ref-type="fig">Figure 2A</xref>). To overview the changes in the phosphorylation activity in the pathway network, the signature proteins are highlighted in the pathway maps. The signature proteins with increased (up) or decreased (down) phosphorylation levels are colored in orange or blue, respectively. Pathway maps for four functional pathway groups (g1–4) are provided, which include 376 ‘signal transduction’ pathway maps (<xref rid="F2" ref-type="fig">Figure 2B</xref>).</p>
      <fig position="float" id="F2" fig-type="figure">
        <label>Figure 2.</label>
        <caption>
          <p>‘Signature Protein’ section. (A) Phosprof top page. Proteins with significant change in phosphorylation level can be browsed by choosing the tested cell type (MCF7 or K562) and treated drug. (B) Signature proteins are highlighted on a pathway map. The 376 analyzed pathways were divided into four functional groups (g1: RTK pathway; g2: Wnt–Hh pathway; g3: GPCR pathway and g4: Cell Death pathway), according to the Reactome classification. (C) Signature proteins of K562 cells under treatment with the SRC inhibitor bosutinib. Data type (Std: standardized data or Raw: raw data), analysis type (RP: rank products or Pearson) and thresholds (Top 50/100/150/200 or <italic toggle="yes">P</italic>-value) can be selected. (D) Enlarged view after searching for SRC on the pathway map. (E) The nodes of the pathway map are linked to the ‘details of the protein’ page. Detailed information includes the gene symbols, amino acid sequences and the disorder scores. This page is also connected to the PDB web site and the protein tertiary structures.</p>
        </caption>
        <graphic xlink:href="baac072f2" position="float"/>
      </fig>
      <p>For example, the signature proteins for the Proto-oncogene tyrosine-protein kinase (SRC)/Abl kinase inhibitor bosutinib (<xref rid="R17" ref-type="bibr">17</xref>, <xref rid="R18" ref-type="bibr">18</xref>) can be browsed in the RTK pathway group. This pathway group includes SRC, the target of bosutinib, and the related signaling molecules (<xref rid="F2" ref-type="fig">Figure 2C and D</xref>). In K562 cells, eight known tyrosine substrates of SRC (annotated in PhosphositePlus) were included in the top 50 signature proteins downregulated by bosutinib. Each node in a pathway map represents a signaling molecule. A list of significant pathways that include the protein of interest can be visualized by hovering the cursor over the node. The nodes are directed to the ‘Details of Protein’ page (<xref rid="F2" ref-type="fig">Figure 2E</xref>). Detailed information includes their gene symbols, amino acid sequences and the disorder scores obtained using IUPred (<xref rid="R15" ref-type="bibr">15</xref>). This page is also connected to the PDB web site via UNIPROT ID and links to the protein tertiary structures with PDB IDs to guide the sequence–structure relationship in the proteins. The tertiary structure of the PDB ENTITY with the longest sequence was selected and visualized using Mol* viewer web application (<xref rid="R19" ref-type="bibr">19</xref>). Tyrosine residues in the structure are displayed as a ball-and-stick model (Section 2.4 <xref rid="s7" ref-type="sec">Supplementary Material</xref>).</p>
    </sec>
    <sec id="s5-s2">
      <title>Pathway</title>
      <p>Based on the distribution of the signature proteins, we estimated the significance of the 376 pathways by enrichment analysis. Significant pathways are colored on the hierarchical tree in the ‘Pathway’ section (<xref rid="F3" ref-type="fig">Figure 3A</xref>) and provide means to review the analysis results in the interconnected pathways. The pathway hierarchy was constructed according to Reactome, and each pathway node is linked to the original Reactome site to provide more detailed information. In the pathway hierarchy, significant pathways with upregulated (Up), downregulated (Down) or both (UpDown) signatures are colored in orange, blue or both, respectively. The pathways of the higher stratum of the significant pathways are displayed in a paler shade of their respective color.</p>
      <fig position="float" id="F3" fig-type="figure">
        <label>Figure 3.</label>
        <caption>
          <p>‘Pathway’ section. (A) Significant pathways with Up, Down or both (UpDown) signatures are displayed in the tree form, according to the pathway ontology classification of Reactome. The number of signature proteins for pathway analysis can be selected (top 50/100/150/200 or <italic toggle="yes">P</italic>-value &lt; 0.05). (B) The multi-targeted RTK inhibitor sunitinib malate downregulates the ‘Signaling by Receptor Tyrosine Kinases’ pathways, including the drug target-related pathways (arrowhead).</p>
        </caption>
        <graphic xlink:href="baac072f3" position="float"/>
      </fig>
      <p>For example, significant pathways of the cells treated with sunitinib malate, a multi-targeted RTK inhibitor of Vascular endothelial growth factor receptor 2 (VEGFR2), Platelet-derived growth factor receptor beta (PDGFRβ) and Tyrosine-protein kinase Kit (KIT) (<xref rid="R20" ref-type="bibr">20</xref>), are shown in pathway hierarchy tree in the ‘Pathway’ section (<xref rid="F3" ref-type="fig">Figure 3A</xref>). We confirmed that their known target-related pathways (signaling by Stem cell factor (SCF)-KIT, Platelet-derived growth factor (PDGF), and Vascular endothelial growth factor (VEGF)) are shown to be downregulated under the pathway node of ‘Signaling by Receptor Tyrosine Kinase (RTK)’ on the hierarchal tree, when the significant pathways with downregulated signatures are selected (<xref rid="F3" ref-type="fig">Figure 3B</xref>, blue arrowhead).</p>
    </sec>
    <sec id="s5-s3">
      <title>Pathway comparison</title>
      <p>To examine the functional similarities and differences of the 94 drugs, significant pathways of selected drugs were compared and displayed in a Venn diagram in the ‘Compare Pathway’ section. Here, significant pathways among five or fewer drugs of interest can be compared with variable thresholds. For example, the significant pathways of five RTK inhibitors (axitinib, sunitinib malate, orantinib, CP673451 and dacomitinib) (<xref rid="R20" ref-type="bibr">20–24</xref>) were compared (<xref rid="F4" ref-type="fig">Figure 4</xref>). A Venn diagram of the significant pathways with upregulated and/or downregulated signatures is provided. Of the 16 pathways of the higher pathway stratum (pathway stratum = 2), the ‘Signaling by Receptor Tyrosine Kinases’ pathway was commonly downregulated in K562 cells by all of those five drugs (<xref rid="F4" ref-type="fig">Figure 4A</xref>). In the lower pathway stratum (pathway stratum = 3), ‘Signaling by VEGF’ was commonly downregulated by axitinib, sunitinib malate and orantinib, and ‘Signaling by PDGF’ was downregulated by sunitinib malate, orantinib and CP673451, which is consistent with the known drug functions (<xref rid="F4" ref-type="fig">Figure 4B</xref>). PDGFR is a target molecule of axitinib, but ‘Signaling by PDGF’ was not observed to be significant in these analysis conditions. This may be because axitinib is more specific for VEGFRs (The half maximal inhibitory concentration (IC50) = 0.1–0.3 nM) than for PDGFRB (1.6 nM) (<xref rid="R21" ref-type="bibr">21</xref>). Similarly, cellular responses to different drugs can be compared in the context of pathways at various levels of pathway hierarchy.</p>
      <fig position="float" id="F4" fig-type="figure">
        <label>Figure 4.</label>
        <caption>
          <p>‘Compare Pathway’ section. Five inhibitory drugs of the protein tyrosine kinase pathway were selected. (A) In the higher pathway hierarchy (pathway stratum = 2), five drugs commonly downregulated the ‘Signaling by Receptor Tyrosine Kinases’. (B) At lower pathway hierarchy, five drugs showed various specificities for pathway activities. (C) The drug information and common pathway results are summarized.</p>
        </caption>
        <graphic xlink:href="baac072f4" position="float"/>
      </fig>
    </sec>
    <sec id="s5-s4">
      <title>Drug search</title>
      <p>All the 94 drugs examined in Phosprof are listed in the ‘Drug List’ section with detailed information, including the formulas, Chemical Abstracts Service Registry Numbers (CAS) and SMILES, and are linked to the PubChem site (<xref rid="R25" ref-type="bibr">25</xref>). Other compounds can be searched for the phosphorylation profile of drugs with molecular similarity in the ‘Drug Search’ section. By entering the SMILES or Structure Data File (SDF) of a compound of interest, similarity indexes with the 94 drugs are provided as Tanimoto coefficient scores. For example, compounds similar to gamma-aminobutyric acid (GABA) were searched using its SMILES form. GABA is an inhibitory neurotransmitter whose proper regulation is necessary for normal neural functions (<xref rid="R26" ref-type="bibr">26</xref>). Using GABA as a query, gabapentin and gabapentin HCl were identified to have relatively high Tanimoto coefficient scores (<xref rid="F5" ref-type="fig">Figure 5A</xref>). Gabapentin is a GABA analog used to treat seizures and neuropathic pain (<xref rid="R27" ref-type="bibr">27</xref>, <xref rid="R28" ref-type="bibr">28</xref>). The ‘Product name’ is linked to the ‘Signature Protein’ section for the corresponding drug (<xref rid="F5" ref-type="fig">Figure 5B</xref>).</p>
      <fig position="float" id="F5" fig-type="figure">
        <label>Figure 5.</label>
        <caption>
          <p>‘Drug Search’ tool. (A) Similarity search for GABA (SMILES: C(CC(=O)O)CN). Product names of similar drugs in Phosprof are listed with the Tanimoto coefficient score. (B) Product Name in the list (A) is linked to the Signature Protein section.</p>
        </caption>
        <graphic xlink:href="baac072f5" position="float"/>
      </fig>
    </sec>
  </sec>
  <sec id="s6">
    <title>Discussion</title>
    <p>We measured phosphorylation profiles of drug-treated cells using protein arrays and visualized the results of their pathway analysis. Pathway analysis of signal transduction has been extensively performed using microarrays or sequencing data (<xref rid="R29" ref-type="bibr">29</xref>, <xref rid="R30" ref-type="bibr">30</xref>). Because signal transduction usually occurs through interconnected pathways that have multiple paths for various signals (<xref rid="R31" ref-type="bibr">31</xref>), it becomes challenging to precisely define pathways responsible by analyzing gene expression data, which are the final output of signal transduction processes. Pathway analysis using phosphorylation profiles is beneficial to examine the molecular bases of signal transduction from a different viewpoint.</p>
    <p>In this study, we presented a new database involving a new dataset of cells treated with 94 drugs whose major target molecules or pathways are known. In the ‘Signature Protein’ section, we provided our analyzed results on pathway maps, and we showed that the phosphorylation level of the target protein SRC was significantly downregulated upon treatment with the SRC/Abl kinase inhibitor bosutinib. Based on the distribution of these signature proteins, we performed pathway analysis and showed the results in the ‘Pathway’ section. In this section, we confirmed that the pathways related to the known target of the multi-targeted RTK inhibitor sunitinib malate are downregulated under the RTK pathway node on the hierarchal tree.</p>
    <p>Comparison of significant pathways between different drugs allowed the investigation of common and unique pathways affected under the corresponding drug response. Given that the pathways are interconnected and functionally related, we compared the list of significant pathways for different drugs in various levels of pathway hierarchy. We visualized the results using a Venn diagram in the ‘Compare Pathway’ section. We validated that the resultant common or unique pathways of the selected RTK inhibitors are associated with the known functional similarities or differences of these drugs. This would be helpful to examine the relationships of the input (drug) and output (functional or adverse effects) of signal transduction processes in future studies. In the ‘Drug Search’ section, one can search for predicted phosphorylation profiles based on drug similarity and use the information for functional analysis of analog-based designed drugs.</p>
    <p>Collectively, Phosprof provides drug response profiles by analyzing the signal transduction activity at the pathway level. It is expected to help better understand different drug responses by providing additional insights into multi-omics data studies. We present a unique measurement and analysis strategy that differs from proteomics with mass spectrometry and aims for ‘fine omics’ in phosphorylation, keeping comprehensiveness in mind to fill the knowledge gap among the conventional omics analysis layers.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>baac072_Supp</label>
      <media xlink:href="baac072_supp.zip">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack id="ack1">
    <title>Acknowledgements</title>
    <p>We thank K. Suzuki for technical assistance with web site preparation.</p>
  </ack>
  <sec id="s7">
    <title>Supplementary data</title>
    <p><xref rid="sup1" ref-type="supplementary-material">Supplementary data</xref> are available at <italic toggle="yes">Database</italic> Online.</p>
  </sec>
  <sec id="s8">
    <title>Funding</title>
    <p>Japan Agency for Medical Research and Development (21ae0101074s0203); Life Science Database Integration Project of the Japan Science and Technology Agency (to K.F., in part).</p>
  </sec>
  <sec id="s9">
    <title>Conflict of interest</title>
    <p>The authors declare that they have no conflicts of interest.</p>
  </sec>
  <sec sec-type="data-availability" id="s10">
    <title>Data availability</title>
    <p>Phosprof is available at <ext-link xlink:href="https://phosprof.medals.jp" ext-link-type="uri">https://phosprof.medals.jp</ext-link>.</p>
  </sec>
  <ref-list id="ref1">
    <title>References</title>
    <ref id="R1">
      <label>1.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Manning</surname><given-names>G.</given-names></string-name>, <string-name><surname>Whyte</surname><given-names>D.B.</given-names></string-name>, <string-name><surname>Martinez</surname><given-names>R.</given-names></string-name></person-group><etal>et al.</etal> (<year>2002</year>) <article-title>The protein kinase complement of the human genome</article-title>. <source><italic toggle="yes">Science</italic></source>, <volume>298</volume>, <fpage>1912</fpage>–<lpage>1934</lpage>.doi: <pub-id pub-id-type="doi">10.1126/science.1075762</pub-id>.<pub-id pub-id-type="pmid">12471243</pub-id></mixed-citation>
    </ref>
    <ref id="R2">
      <label>2.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bhalla</surname><given-names>U.S.</given-names></string-name> and <string-name><surname>Iyengar</surname><given-names>R.</given-names></string-name></person-group> (<year>1999</year>) <article-title>Emergent properties of networks of biological signaling pathways</article-title>. <source><italic toggle="yes">Science</italic></source>, <volume>283</volume>, <fpage>381</fpage>–<lpage>387</lpage>.doi: <pub-id pub-id-type="doi">10.1126/science.283.5400.381</pub-id>.<pub-id pub-id-type="pmid">9888852</pub-id></mixed-citation>
    </ref>
    <ref id="R3">
      <label>3.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Blume-Jensen</surname><given-names>P.</given-names></string-name> and <string-name><surname>Hunter</surname><given-names>T.</given-names></string-name></person-group> (<year>2001</year>) <article-title>Oncogenic kinase signalling</article-title>. <source><italic toggle="yes">Nature</italic></source>, <volume>411</volume>, <fpage>355</fpage>–<lpage>365</lpage>.doi: <pub-id pub-id-type="doi">10.1038/35077225</pub-id>.<pub-id pub-id-type="pmid">11357143</pub-id></mixed-citation>
    </ref>
    <ref id="R4">
      <label>4.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ramazi</surname><given-names>S.</given-names></string-name> and <string-name><surname>Zahiri</surname><given-names>J.</given-names></string-name></person-group> (<year>2021</year>) <article-title>Posttranslational modifications in proteins: resources, tools and prediction methods</article-title>. <source><italic toggle="yes">Database (Oxford)</italic></source>, <volume>2021</volume>, <page-range>baab012</page-range>.doi: <pub-id pub-id-type="doi">10.1093/database/baab012</pub-id>.</mixed-citation>
    </ref>
    <ref id="R5">
      <label>5.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hornbeck</surname><given-names>P.V.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>B.</given-names></string-name>, <string-name><surname>Murray</surname><given-names>B.</given-names></string-name></person-group><etal>et al.</etal> (<year>2015</year>) <article-title>PhosphoSitePlus, 2014: mutations, PTMs and recalibrations</article-title>. <source><italic toggle="yes">Nucleic Acids Res.</italic></source>, <volume>43</volume>, <fpage>D512</fpage>–<lpage>D520</lpage>.doi: <pub-id pub-id-type="doi">10.1093/nar/gku1267</pub-id>.<pub-id pub-id-type="pmid">25514926</pub-id></mixed-citation>
    </ref>
    <ref id="R6">
      <label>6.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gnad</surname><given-names>F.</given-names></string-name>, <string-name><surname>Gunawardena</surname><given-names>J.</given-names></string-name> and <string-name><surname>Mann</surname><given-names>M.</given-names></string-name></person-group> (<year>2011</year>) <article-title>PHOSIDA 2011: the posttranslational modification database</article-title>. <source><italic toggle="yes">Nucleic Acids Res.</italic></source>, <volume>39</volume>, <fpage>D253</fpage>–<lpage>D260</lpage>.doi: <pub-id pub-id-type="doi">10.1093/nar/gkaq1159</pub-id>.<pub-id pub-id-type="pmid">21081558</pub-id></mixed-citation>
    </ref>
    <ref id="R7">
      <label>7.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hennrich</surname><given-names>M.L.</given-names></string-name> and <string-name><surname>Gavin</surname><given-names>A.C.</given-names></string-name></person-group> (<year>2015</year>) <article-title>Quantitative mass spectrometry of posttranslational modifications: keys to confidence</article-title>. <source><italic toggle="yes">Sci. Signal.</italic></source>, <volume>8</volume>, <page-range>re5</page-range>.doi: <pub-id pub-id-type="doi">10.1126/scisignal.aaa6466</pub-id>.</mixed-citation>
    </ref>
    <ref id="R8">
      <label>8.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ptacek</surname><given-names>J.</given-names></string-name>, <string-name><surname>Devgan</surname><given-names>G.</given-names></string-name>, <string-name><surname>Michaud</surname><given-names>G.</given-names></string-name></person-group><etal>et al.</etal> (<year>2005</year>) <article-title>Global analysis of protein phosphorylation in yeast</article-title>. <source><italic toggle="yes">Nature</italic></source>, <volume>438</volume>, <fpage>679</fpage>–<lpage>684</lpage>.doi: <pub-id pub-id-type="doi">10.1038/nature04187</pub-id>.<pub-id pub-id-type="pmid">16319894</pub-id></mixed-citation>
    </ref>
    <ref id="R9">
      <label>9.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Woodard</surname><given-names>C.L.</given-names></string-name>, <string-name><surname>Goodwin</surname><given-names>C.R.</given-names></string-name>, <string-name><surname>Wan</surname><given-names>J.</given-names></string-name></person-group><etal>et al.</etal> (<year>2013</year>) <article-title>Profiling the dynamics of a human phosphorylome reveals new components in HGF/c-Met signaling</article-title>. <source><italic toggle="yes">PLoS One</italic></source>, <volume>8</volume>, <page-range>e72671</page-range>.doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0072671</pub-id>.</mixed-citation>
    </ref>
    <ref id="R10">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hu</surname><given-names>J.</given-names></string-name>, <string-name><surname>Rho</surname><given-names>H.S.</given-names></string-name>, <string-name><surname>Newman</surname><given-names>R.H.</given-names></string-name></person-group><etal>et al.</etal> (<year>2014</year>) <article-title>PhosphoNetworks: a database for human phosphorylation networks</article-title>. <source><italic toggle="yes">Bioinformatics</italic></source>, <volume>30</volume>, <fpage>141</fpage>–<lpage>142</lpage>.doi: <pub-id pub-id-type="doi">10.1093/bioinformatics/btt627</pub-id>.<pub-id pub-id-type="pmid">24227675</pub-id></mixed-citation>
    </ref>
    <ref id="R11">
      <label>11.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kagiwada</surname><given-names>H.</given-names></string-name>, <string-name><surname>Kiboku</surname><given-names>T.</given-names></string-name>, <string-name><surname>Matsuo</surname><given-names>H.</given-names></string-name></person-group><etal>et al.</etal> (<year>2021</year>) <article-title>Assessing the activation/inhibition of tyrosine kinase-related pathways with a newly developed platform</article-title>. <source><italic toggle="yes">Proteomics</italic></source>, <volume>21</volume>, <page-range>e2000251</page-range>.doi: <pub-id pub-id-type="doi">10.1002/pmic.202000251</pub-id>.</mixed-citation>
    </ref>
    <ref id="R12">
      <label>12.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fabregat</surname><given-names>A.</given-names></string-name>, <string-name><surname>Jupe</surname><given-names>S.</given-names></string-name>, <string-name><surname>Matthews</surname><given-names>L.</given-names></string-name></person-group><etal>et al.</etal> (<year>2018</year>) <article-title>The Reactome pathway knowledgebase</article-title>. <source><italic toggle="yes">Nucleic Acids Res.</italic></source>, <volume>46</volume>, <fpage>D649</fpage>–<lpage>D655</lpage>.doi: <pub-id pub-id-type="doi">10.1093/nar/gkx1132</pub-id>.<pub-id pub-id-type="pmid">29145629</pub-id></mixed-citation>
    </ref>
    <ref id="R13">
      <label>13.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tomonari</surname><given-names>T.</given-names></string-name>, <string-name><surname>Sato</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Tanaka</surname><given-names>H.</given-names></string-name></person-group><etal>et al.</etal> (<year>2020</year>) <article-title>Potential use of lenvatinib for patients with unresectable hepatocellular carcinoma including after treatment with sorafenib: real-world evidence and <italic toggle="yes">in vitro</italic> assessment via protein phosphorylation array</article-title>. <source><italic toggle="yes">Oncotarget</italic></source>, <volume>11</volume>, <fpage>2531</fpage>–<lpage>2542</lpage>.doi: <pub-id pub-id-type="doi">10.18632/oncotarget.27640</pub-id>.<pub-id pub-id-type="pmid">32655838</pub-id></mixed-citation>
    </ref>
    <ref id="R14">
      <label>14.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Manabe</surname><given-names>T.</given-names></string-name>, <string-name><surname>Yasuda</surname><given-names>H.</given-names></string-name>, <string-name><surname>Terai</surname><given-names>H.</given-names></string-name></person-group><etal>et al.</etal> (<year>2020</year>) <article-title>IGF2 autocrine-mediated IGF1R activation is a clinically relevant mechanism of osimertinib resistance in lung cancer</article-title>. <source><italic toggle="yes">Mol. Cancer Res.</italic></source>, <volume>18</volume>, <fpage>549</fpage>–<lpage>559</lpage>.doi: <pub-id pub-id-type="doi">10.1158/1541-7786.MCR-19-0956</pub-id>.<pub-id pub-id-type="pmid">31941753</pub-id></mixed-citation>
    </ref>
    <ref id="R15">
      <label>15.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dosztanyi</surname><given-names>Z.</given-names></string-name></person-group> (<year>2018</year>) <article-title>Prediction of protein disorder based on IUPred</article-title>. <source><italic toggle="yes">Protein Sci.</italic></source>, <volume>27</volume>, <fpage>331</fpage>–<lpage>340</lpage>.doi: <pub-id pub-id-type="doi">10.1002/pro.3334</pub-id>.<pub-id pub-id-type="pmid">29076577</pub-id></mixed-citation>
    </ref>
    <ref id="R16">
      <label>16.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Berman</surname><given-names>H.M.</given-names></string-name>, <string-name><surname>Westbrook</surname><given-names>J.</given-names></string-name>, <string-name><surname>Feng</surname><given-names>Z.</given-names></string-name></person-group><etal>et al.</etal> (<year>2000</year>) <article-title>The Protein Data Bank</article-title>. <source><italic toggle="yes">Nucleic Acids Res.</italic></source>, <volume>28</volume>, <fpage>235</fpage>–<lpage>242</lpage>.doi: <pub-id pub-id-type="doi">10.1093/nar/28.1.235</pub-id>.<pub-id pub-id-type="pmid">10592235</pub-id></mixed-citation>
    </ref>
    <ref id="R17">
      <label>17.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Boschelli</surname><given-names>D.H.</given-names></string-name>, <string-name><surname>Ye</surname><given-names>F.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y.D.</given-names></string-name></person-group><etal>et al.</etal> (<year>2001</year>) <article-title>Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity</article-title>. <source><italic toggle="yes">J. Med. Chem.</italic></source>, <volume>44</volume>, <fpage>3965</fpage>–<lpage>3977</lpage>.doi: <pub-id pub-id-type="doi">10.1021/jm0102250</pub-id>.<pub-id pub-id-type="pmid">11689083</pub-id></mixed-citation>
    </ref>
    <ref id="R18">
      <label>18.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Golas</surname><given-names>J.M.</given-names></string-name>, <string-name><surname>Arndt</surname><given-names>K.</given-names></string-name>, <string-name><surname>Etienne</surname><given-names>C.</given-names></string-name></person-group><etal>et al.</etal> (<year>2003</year>) <article-title>SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice</article-title>. <source><italic toggle="yes">Cancer Res.</italic></source>, <volume>63</volume>, <fpage>375</fpage>–<lpage>381</lpage>.<pub-id pub-id-type="pmid">12543790</pub-id></mixed-citation>
    </ref>
    <ref id="R19">
      <label>19.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sehnal</surname><given-names>D.</given-names></string-name>, <string-name><surname>Bittrich</surname><given-names>S.</given-names></string-name>, <string-name><surname>Deshpande</surname><given-names>M.</given-names></string-name></person-group><etal>et al.</etal> (<year>2021</year>) <article-title>Mol* Viewer: modern web app for 3D visualization and analysis of large biomolecular structures</article-title>. <source><italic toggle="yes">Nucleic Acids Res.</italic></source>, <volume>49</volume>, <fpage>W431</fpage>–<lpage>W437</lpage>.doi: <pub-id pub-id-type="doi">10.1093/nar/gkab314</pub-id>.<pub-id pub-id-type="pmid">33956157</pub-id></mixed-citation>
    </ref>
    <ref id="R20">
      <label>20.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sun</surname><given-names>L.</given-names></string-name>, <string-name><surname>Liang</surname><given-names>C.</given-names></string-name>, <string-name><surname>Shirazian</surname><given-names>S.</given-names></string-name></person-group><etal>et al.</etal> (<year>2003</year>) <article-title>Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase</article-title>. <source><italic toggle="yes">J. Med. Chem.</italic></source>, <volume>46</volume>, <fpage>1116</fpage>–<lpage>1119</lpage>.doi: <pub-id pub-id-type="doi">10.1021/jm0204183</pub-id>.<pub-id pub-id-type="pmid">12646019</pub-id></mixed-citation>
    </ref>
    <ref id="R21">
      <label>21.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hu-Lowe</surname><given-names>D.D.</given-names></string-name>, <string-name><surname>Zou</surname><given-names>H.Y.</given-names></string-name>, <string-name><surname>Grazzini</surname><given-names>M.L.</given-names></string-name></person-group><etal>et al.</etal> (<year>2008</year>) <article-title>Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3</article-title>. <source><italic toggle="yes">Clin. Cancer Res.</italic></source>, <volume>14</volume>, <fpage>7272</fpage>–<lpage>7283</lpage>.doi: <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-08-0652</pub-id>.<pub-id pub-id-type="pmid">19010843</pub-id></mixed-citation>
    </ref>
    <ref id="R22">
      <label>22.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Laird</surname><given-names>A.D.</given-names></string-name>, <string-name><surname>Vajkoczy</surname><given-names>P.</given-names></string-name>, <string-name><surname>Shawver</surname><given-names>L.K.</given-names></string-name></person-group><etal>et al.</etal> (<year>2000</year>) <article-title>SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors</article-title>. <source><italic toggle="yes">Cancer Res.</italic></source>, <volume>60</volume>, <fpage>4152</fpage>–<lpage>4160</lpage>.<pub-id pub-id-type="pmid">10945623</pub-id></mixed-citation>
    </ref>
    <ref id="R23">
      <label>23.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Roberts</surname><given-names>W.G.</given-names></string-name>, <string-name><surname>Whalen</surname><given-names>P.M.</given-names></string-name>, <string-name><surname>Soderstrom</surname><given-names>E.</given-names></string-name></person-group><etal>et al.</etal> (<year>2005</year>) <article-title>Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451</article-title>. <source><italic toggle="yes">Cancer Res.</italic></source>, <volume>65</volume>, <fpage>957</fpage>–<lpage>966</lpage>.doi: <pub-id pub-id-type="doi">10.1158/0008-5472.957.65.3</pub-id>.<pub-id pub-id-type="pmid">15705896</pub-id></mixed-citation>
    </ref>
    <ref id="R24">
      <label>24.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Engelman</surname><given-names>J.A.</given-names></string-name>, <string-name><surname>Zejnullahu</surname><given-names>K.</given-names></string-name>, <string-name><surname>Gale</surname><given-names>C.M.</given-names></string-name></person-group><etal>et al.</etal> (<year>2007</year>) <article-title>PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib</article-title>. <source><italic toggle="yes">Cancer Res.</italic></source>, <volume>67</volume>, <fpage>11924</fpage>–<lpage>11932</lpage>.doi: <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-1885</pub-id>.<pub-id pub-id-type="pmid">18089823</pub-id></mixed-citation>
    </ref>
    <ref id="R25">
      <label>25.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kim</surname><given-names>S.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>J.</given-names></string-name>, <string-name><surname>Cheng</surname><given-names>T.</given-names></string-name></person-group><etal>et al.</etal> (<year>2021</year>) <article-title>PubChem in 2021: new data content and improved web interfaces</article-title>. <source><italic toggle="yes">Nucleic Acids Res.</italic></source>, <volume>49</volume>, <fpage>D1388</fpage>–<lpage>D1395</lpage>.doi: <pub-id pub-id-type="doi">10.1093/nar/gkaa971</pub-id>.<pub-id pub-id-type="pmid">33151290</pub-id></mixed-citation>
    </ref>
    <ref id="R26">
      <label>26.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hu</surname><given-names>H.</given-names></string-name>, <string-name><surname>Gan</surname><given-names>J.</given-names></string-name> and <string-name><surname>Jonas</surname><given-names>P.</given-names></string-name></person-group> (<year>2014</year>) <article-title>Interneurons. Fast-spiking, parvalbumin(+) GABAergic interneurons: from cellular design to microcircuit function</article-title>. <source><italic toggle="yes">Science</italic></source>, <volume>345</volume>, <page-range>1255263</page-range>.doi: <pub-id pub-id-type="doi">10.1126/science.1255263</pub-id>.</mixed-citation>
    </ref>
    <ref id="R27">
      <label>27.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pan</surname><given-names>H.L.</given-names></string-name>, <string-name><surname>Eisenach</surname><given-names>J.C.</given-names></string-name> and <string-name><surname>Chen</surname><given-names>S.R.</given-names></string-name></person-group> (<year>1999</year>) <article-title>Gabapentin suppresses ectopic nerve discharges and reverses allodynia in neuropathic rats</article-title>. <source><italic toggle="yes">J. Pharmacol. Exp. Ther.</italic></source>, <volume>288</volume>, <fpage>1026</fpage>–<lpage>1030</lpage>.<pub-id pub-id-type="pmid">10027839</pub-id></mixed-citation>
    </ref>
    <ref id="R28">
      <label>28.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sills</surname><given-names>G.J.</given-names></string-name> and <string-name><surname>Rogawski</surname><given-names>M.A.</given-names></string-name></person-group> (<year>2020</year>) <article-title>Mechanisms of action of currently used antiseizure drugs</article-title>. <source><italic toggle="yes">Neuropharmacology</italic></source>, <volume>168</volume>, <page-range>107966</page-range>.doi: <pub-id pub-id-type="doi">10.1016/j.neuropharm.2020.107966</pub-id>.</mixed-citation>
    </ref>
    <ref id="R29">
      <label>29.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhao</surname><given-names>X.M.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>R.S.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>L.</given-names></string-name></person-group><etal>et al.</etal> (<year>2008</year>) <article-title>Uncovering signal transduction networks from high-throughput data by integer linear programming</article-title>. <source><italic toggle="yes">Nucleic Acids Res.</italic></source>, <volume>36</volume>, <page-range>e48</page-range>.doi: <pub-id pub-id-type="doi">10.1093/nar/gkn145</pub-id>.</mixed-citation>
    </ref>
    <ref id="R30">
      <label>30.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Geistlinger</surname><given-names>L.</given-names></string-name>, <string-name><surname>Csaba</surname><given-names>G.</given-names></string-name>, <string-name><surname>Santarelli</surname><given-names>M.</given-names></string-name></person-group><etal>et al.</etal> (<year>2021</year>) <article-title>Toward a gold standard for benchmarking gene set enrichment analysis</article-title>. <source><italic toggle="yes">Brief. Bioinformatics</italic></source>, <volume>22</volume>, <fpage>545</fpage>–<lpage>556</lpage>.doi: <pub-id pub-id-type="doi">10.1093/bib/bbz158</pub-id>.<pub-id pub-id-type="pmid">32026945</pub-id></mixed-citation>
    </ref>
    <ref id="R31">
      <label>31.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Natarajan</surname><given-names>M.</given-names></string-name>, <string-name><surname>Lin</surname><given-names>K.M.</given-names></string-name>, <string-name><surname>Hsueh</surname><given-names>R.C.</given-names></string-name></person-group><etal>et al.</etal> (<year>2006</year>) <article-title>A global analysis of cross-talk in a mammalian cellular signalling network</article-title>. <source><italic toggle="yes">Nat. Cell Biol.</italic></source>, <volume>8</volume>, <fpage>571</fpage>–<lpage>580</lpage>.doi: <pub-id pub-id-type="doi">10.1038/ncb1418</pub-id>.<pub-id pub-id-type="pmid">16699502</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
